SM08502 + abiraterone + prednisone

This is a **combination therapy** of SM08502, abiraterone, and prednisone. - **SM08502** is an oral small-molecule inhibitor of CDC-like kinase (CLK), specifically potent against CLK2 and CLK3, developed by Samumed. It disrupts spliceosome activity and inhibits the Wnt/β-catenin signaling pathway by altering alternative splicing and reducing Wnt pathway-related gene expression. It is in clinical development for advanced solid tumors, including prostate and pancreatic cancers, and received orphan drug designation for pancreatic cancer[1][3][4][6][7]. - **Abiraterone** is an androgen biosynthesis inhibitor, more specifically a selective, irreversible inhibitor of the enzyme steroid 17α-hydroxylase/17,20-lyase (CYP17A1), blocking androgen and cortisol production. It is approved in combination with prednisone for metastatic castration-resistant and metastatic castration-sensitive prostate cancer[2][5]. - **Prednisone** is a synthetic glucocorticoid administered alongside abiraterone to manage mineralocorticoid excess caused by androgen synthesis inhibition and to serve as glucocorticoid replacement therapy[5]. The combination is of investigational interest for treating advanced prostate cancer and potentially other solid tumors.